Published online May 27, 2021. doi: 10.4240/wjgs.v13.i5.429
Peer-review started: January 10, 2021
First decision: February 11, 2021
Revised: February 27, 2021
Accepted: April 4, 2021
Article in press: April 4, 2021
Published online: May 27, 2021
Processing time: 130 Days and 20.9 Hours
The potential survival benefit of neoadjuvant chemotherapy (NC) in patients with advanced gastric cancer has been widely recognized.
With the development of minimally invasive surgery, which is represented by laparoscopy, the effect of NC on the safety of laparoscopic gastrectomy remains to be further explored.
To compare the short-term outcomes of laparoscopic total gastrectomy (LTG) after NC (NC-LTG) with LTG alone.
A total of 92 patients who underwent NC-LTG and 381 patients who received LTG alone at the Chinese PLA General Hospital between September 2015 and September 2020 were retrospectively included in our study. We used propensity-score matching (PSM) to balance baseline bias. After 1:1 PSM, 73 patients were included in each group with no statistically significant difference in baseline characteristics.
The NC-LTG group exhibited a longer operation time and increased intraoperative blood loss compared to the LTG group. There were no significant differences in 30-d postoperative morbidity, 30-d severe complication rates, or anastomotic leakage rates. A multivariate analysis showed that an operation time greater than 240 min was an independent risk factor while NC was not an independent risk factor for postoperative complications in LTG.
Despite a longer operation time and more blood loss after NC-LTG, which indicate surgical difficulty, NC-LTG exhibits acceptable short-term outcomes compared to LTG, illustrating the safety and feasibility of NC-LTG.
Further research like multi-institutional retrospective study or randomized controlled trial study is needed to confirm our results and provide high-grade evidence for the appropriate application of NC-LTG.